Our History of Advancing Science
Established in 2003 by world-renowned researchers, our history is deeply rooted in science and our research and development efforts are focused on disease areas with significant unmet need for new treatment options to help improve the lives of patients.
TYMLOS (abaloparatide) Injection was approved on April 28, 2017 by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Radius’ NDA for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis accepted for filing by the US Food and Drug Administration in May 2016.
In November, Radius Health submitted an MAA to the European Medicines Agency, or EMA, for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis, which was validated in December, and is currently undergoing active regulatory assessment by the Committee for Medicinal Products for Human Use of the EMA, or CHMP.
Reports top-line data from the first six months of the ACTIVExtend trial.
Hosts first Investor Day in New York City on November 17.
Reports Phase 3 ACTIVE data for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis.
Elacestrant (RAD1901) Phase 1 in advanced ER+ and HER2- breast cancer trial commences.
Radius completes successful IPO in June.
Abaloparatide-SC Phase 3 extension study commences.
Radius and 3M drug delivery systems announce exclusive agreement for development of transdermal delivery of abaloparatide.
Abaloparatide-TD Phase 2 trial commences.
Radius enters strategic clinical development agreement with Nordic Bioscience.
Abaloparatide-SC Phase 3 ACTIVE trial commences.
Elacestrant (RAD1901) Phase 2a trial commences in vasomotor symptoms.
Abaloparatide-SC Phase 2 trial commences.
Radius in-licenses elacestrant (RAD1901), a selective estrogen receptor degrader (SERD).